The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance
| dc.contributor.author | Aguilar-Recarte, David | |
| dc.contributor.author | Palomer Tarridas, Francesc Xavier | |
| dc.contributor.author | Wahli, Walter | |
| dc.contributor.author | Vázquez Carrera, Manuel | |
| dc.date.accessioned | 2022-03-08T11:54:55Z | |
| dc.date.available | 2022-03-08T11:54:55Z | |
| dc.date.issued | 2021-08-09 | |
| dc.date.updated | 2022-03-08T11:54:55Z | |
| dc.description.abstract | The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR)β/δ show promise. Remarkably, most of the antidiabetic effects of PPARβ/δ agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPARβ/δ-AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPARβ/δ-AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 713706 | |
| dc.identifier.issn | 1661-6596 | |
| dc.identifier.uri | https://hdl.handle.net/2445/183848 | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijms22168555 | |
| dc.relation.ispartof | International Journal of Molecular Sciences, 2021, vol. 22, num. 16, p. 8555 | |
| dc.relation.uri | https://doi.org/10.3390/ijms22168555 | |
| dc.rights | cc-by (c) Aguilar-Recarte, David et al., 2021 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.source | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) | |
| dc.subject.classification | Trastorns del metabolisme dels lípids | |
| dc.subject.classification | Àcids grassos | |
| dc.subject.classification | Receptors nuclears (Bioquímica) | |
| dc.subject.classification | Glucosa | |
| dc.subject.other | Lipid metabolism disorders | |
| dc.subject.other | Fatty acids | |
| dc.subject.other | Nuclear receptors (Biochemistry) | |
| dc.subject.other | Glucose | |
| dc.title | The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1